Related Experiment Videos
Add-on therapy in epilepsy with calcium entry blockers
European Neurology
|January 1, 1986
Summary
Flunarizine, a calcium channel blocker, shows promise in treating epilepsy by reducing seizures in patients resistant to other therapies. This drug effectively crosses the blood-brain barrier with minimal side effects.
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Calcium ions (Ca2+) play a crucial role in neuronal hyperexcitability during epileptic seizures.
- Understanding the mechanisms of paroxysmal depolarization shifts is key to developing new antiepileptic drugs.
Purpose of the Study:
- To investigate the potential antiepileptic activity of calcium (Ca2+) entry blockers.
- To evaluate flunarizine, a calcium channel blocker that penetrates the blood-brain barrier, as a therapeutic agent for epilepsy.
Main Methods:
- Assessment of flunarizine's efficacy in experimental epilepsy models.
- Clinical evaluation through therapeutic trials in patients with therapy-resistant epilepsy.
Main Results:
- Flunarizine demonstrated effectiveness in preclinical epilepsy models.
- Significant seizure reduction was observed in two clinical trials involving patients with refractory epilepsy.
- Flunarizine exhibited a favorable safety profile with mild side effects at therapeutic doses.
Conclusions:
- Calcium (Ca2+) entry blockers, specifically flunarizine, represent a potential therapeutic strategy for epilepsy.
- Flunarizine's ability to cross the blood-brain barrier and its demonstrated efficacy and safety profile support its use in managing difficult-to-treat epilepsy.